
Tyra Biosciences (TYRA) Stock Forecast & Price Target
Tyra Biosciences (TYRA) Analyst Ratings
Bulls say
Tyra Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for targeted oncology and genetically defined conditions using their in-house precision medicine platform, SNAP. With promising drug candidates in their product pipeline and a strong focus on tackling the toxicity and resistance issues associated with first-generation pan-FGFR inhibitors, the company has the potential for success in the market. Additionally, the company's collaboration revenue, discounted cash flow-based valuation, and solid probability of approval for their drug candidates add further support to their positive outlook. However, risks to their price target achievement include potential issues with response maturation, safety events, and insufficient durability or recurrence control. Investors should monitor updates on the program's progress and longer-term data to assess the potential for long-term value creation.
Bears say
Tyra Biosciences is facing potential issues with their new precision medicine platform, SNAP, as their current clinical-stage drug candidates are struggling to demonstrate strong efficacy and tolerability. Furthermore, the company's path to restoring confidence may be hindered by inconsistent dose-level efficacy and potential safety events. With a P/E of over 30 and a relatively high discount rate, there may be an overvaluation of the company's stock, making it a risky investment option.
This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction
Start investing in Tyra Biosciences (TYRA)
Order type
Buy in
Order amount
Est. shares
0 shares